<code id='642341D151'></code><style id='642341D151'></style>
    • <acronym id='642341D151'></acronym>
      <center id='642341D151'><center id='642341D151'><tfoot id='642341D151'></tfoot></center><abbr id='642341D151'><dir id='642341D151'><tfoot id='642341D151'></tfoot><noframes id='642341D151'>

    • <optgroup id='642341D151'><strike id='642341D151'><sup id='642341D151'></sup></strike><code id='642341D151'></code></optgroup>
        1. <b id='642341D151'><label id='642341D151'><select id='642341D151'><dt id='642341D151'><span id='642341D151'></span></dt></select></label></b><u id='642341D151'></u>
          <i id='642341D151'><strike id='642341D151'><tt id='642341D151'><pre id='642341D151'></pre></tt></strike></i>

          Home / hotspot / explore

          explore


          explore

          author:comprehensive    Page View:94
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In